Hamostaseologie最新文献

筛选
英文 中文
Digital Technologies in Hereditary Coagulation Disorders: A Systematic Review. 遗传性凝血疾病的数字技术:系统综述。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2024-12-01 Epub Date: 2024-12-10 DOI: 10.1055/a-2415-8646
Fabian Kahl, Maximilian Kapsecker, Leon Nissen, Laura Bresser, Marie Heinemann, Lara Marie Reimer, Stephan M Jonas
{"title":"Digital Technologies in Hereditary Coagulation Disorders: A Systematic Review.","authors":"Fabian Kahl, Maximilian Kapsecker, Leon Nissen, Laura Bresser, Marie Heinemann, Lara Marie Reimer, Stephan M Jonas","doi":"10.1055/a-2415-8646","DOIUrl":"10.1055/a-2415-8646","url":null,"abstract":"<p><strong>Background: </strong> This systematic review aims to comprehensively survey digital technologies used in the prevention, diagnosis, and treatment of hereditary blood coagulation disorders.</p><p><strong>Methods: </strong> The systematic review was performed according to the PRISMA guidelines. A systematic search was conducted on PubMed on January 29, 2024. Articles were excluded if they were reviews, meta-analyses, or systematic reviews. Articles were included if they were published from January 1, 2014, onward, written in English, described an actual application of digital tools, were in the context of hereditary coagulation disorders, and involved studies or trials on humans or human data with at least three subjects.</p><p><strong>Results: </strong> The initial PubMed search on January 29, 2024, identified 2,843 articles, with 672 from January 1, 2014, onward. After screening, 21 articles met the exclusion and inclusion criteria. Among these, 12 focused on artificial intelligence (AI) technologies and 9 on digital applications. AI was predominantly used for diagnosis (five studies) and treatment (four studies), while digital applications were mainly used for treatment (eight studies). Most studies addressed hemophilia A, with a smaller number including hemophilia B or von Willebrand disease.</p><p><strong>Discussion: </strong> The findings reveal a lack of intervention studies in the prevention, diagnosis, and treatment. However, digital tools, including AI and digital applications, are increasingly used in managing hereditary coagulation disorders. AI enhances diagnostic accuracy and personalizes treatment, while digital applications improve patient care and engagement. Despite these advancements, study biases and design limitations indicate the need for further research to fully harness the potential of these technologies.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"44 6","pages":"446-458"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11631203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Keine genetische Korrelation zwischen Rauchen und venösen Thromboembolien. 吸烟和静脉血栓栓塞之间没有遗传相关性。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2024-12-01 Epub Date: 2024-12-10 DOI: 10.1055/s-0044-1800985
{"title":"Keine genetische Korrelation zwischen Rauchen und venösen Thromboembolien.","authors":"","doi":"10.1055/s-0044-1800985","DOIUrl":"https://doi.org/10.1055/s-0044-1800985","url":null,"abstract":"","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"44 6","pages":"426"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digenic Inheritance of PROC and SERPINC1 Mutations Contributes to Multiple Sites Venous Thrombosis. PROC 和 SERPINC1 基因突变的双基因遗传导致多部位静脉血栓形成。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2024-12-01 Epub Date: 2024-01-15 DOI: 10.1055/a-2212-1565
Xiangui Li, Jiabao Zhu, Fanzhen Lv, Wenqi Ma, Weimin Zhou, Wenwen Zhang
{"title":"Digenic Inheritance of PROC and SERPINC1 Mutations Contributes to Multiple Sites Venous Thrombosis.","authors":"Xiangui Li, Jiabao Zhu, Fanzhen Lv, Wenqi Ma, Weimin Zhou, Wenwen Zhang","doi":"10.1055/a-2212-1565","DOIUrl":"10.1055/a-2212-1565","url":null,"abstract":"<p><p>Venous thromboembolism (VTE) represents a worldwide health challenge, impacting millions of people each year. The genesis of venous thrombosis is influenced in part by genetic components. Hereditary thrombosis is described as a genetically determined susceptibility to VTE. In the present study, a male patient was referred to our department presenting with multiple venous thrombosis events in different locations. Given a lack of identifiable risk factors, we aimed to investigate the possible genetic factor underlying venous thrombosis. Whole-exome sequencing was employed to examine genes linked to inherited thrombophilia in the proband. Putative variants were subsequently confirmed through Sanger sequencing within the family. The proband was identified as carrying two genetic mutations. One is the novel c.400G > C (p.E134Q) mutation affecting the final nucleotide of exon 5 in the PROC gene, potentially impacting splicing. The other is a previously reported heterozygous nonsense variant c.1016G > A (p.W339X) in the SERPINC1 gene. The proband inherited the former from her mother and the latter from her father. The presence of digenic inheritance in the patient reflects the complex phenotype of venous thrombosis and demonstrates the significance of an unbiased approach to detect pathogenic variants, especially in patients with a high risk of hereditary thrombosis.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"472-477"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11631202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139472962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia. 关于定义严重出血表型以指导非严重血友病患者预防治疗的专家意见。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2024-11-12 DOI: 10.1055/a-2411-7416
Christian Pfrepper, Carmen Escuriola Ettingshausen, Robert Klamroth, Johannes Oldenburg, Martin Olivieri
{"title":"Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia.","authors":"Christian Pfrepper, Carmen Escuriola Ettingshausen, Robert Klamroth, Johannes Oldenburg, Martin Olivieri","doi":"10.1055/a-2411-7416","DOIUrl":"10.1055/a-2411-7416","url":null,"abstract":"<p><p>Prophylaxis is the standard of care for patients with severe hemophilia, patients with moderate hemophilia, or those with another congenital bleeding disorder that is associated with a severe bleeding phenotype and/or a high risk of spontaneous life-threatening bleeding. Patients with nonsevere hemophilia (factor VIII [FVIII] ≥ 1%) may also have a bleeding phenotype that requires prophylaxis. To date, however, there are no clear criteria as to when prophylaxis is indicated in these patients. Also, the term \"severe bleeding phenotype (SBPT)\" is neither included in the definitions of the International Society on Thrombosis and Haemostasis (ISTH) nor specified in the World Federation of Hemophilia (WFH) guidelines. Based on our personal experience and available evidence, we propose the criteria we use to define an SBPT and when we consider offering prophylaxis in patients with nonsevere hemophilia. Our proposals can be the basis for discussions in the community about the assessment of SBPT and the initiation of prophylaxis in patients with nonsevere hemophilia without inhibitors.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Adult Patients with Newly Diagnosed or Relapsed Primary Immune Thrombocytopenia in Eastern Austria. 对奥地利东部新诊断或复发的原发性免疫性血小板减少症成人患者的管理。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2024-11-05 DOI: 10.1055/a-2404-0306
Jasmin Rast, Theresa Schramm, Dino Mehic, Michael Fillitz, Tanja Drexel, Veronika Neusiedler-Nicolas, Cihan Ay, Ingrid Pabinger, Johanna Gebhart
{"title":"Management of Adult Patients with Newly Diagnosed or Relapsed Primary Immune Thrombocytopenia in Eastern Austria.","authors":"Jasmin Rast, Theresa Schramm, Dino Mehic, Michael Fillitz, Tanja Drexel, Veronika Neusiedler-Nicolas, Cihan Ay, Ingrid Pabinger, Johanna Gebhart","doi":"10.1055/a-2404-0306","DOIUrl":"10.1055/a-2404-0306","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt; Treatment sequence in primary immune thrombocytopenia (ITP) is based on national and international recommendations, treatment availability, and physician expertise.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt; This article aimed to provide real-world data on treatment sequence and responses to first- and second-line treatments in newly diagnosed and relapsed adult ITP patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt; We analyzed a cohort of 46 adult ITP patients from the Vienna ITP Biobank, who started first-line therapy within 1 week before their first study visit between February 2016 and March 2023. We investigated clinical patient characteristics and patient management in our specialized center and examined the impact of the international ASH guidelines on ITP treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt; Forty-six primary ITP patients, 27 (58.7%) with newly diagnosed ITP and 19 (41.3%) with relapsed ITP, were investigated. Most patients were female (65.2%) with a median platelet count of 9 × 10&lt;sup&gt;9&lt;/sup&gt;/L, and 31 patients (67.4%) had bleeding symptoms. All patients received first-line treatment with oral prednisolone; 15 patients received oral prednisolone combined with intravenous immunoglobulins (IVIGs), which were more commonly administered in newly diagnosed than in relapsed ITP patients. First-line therapy resulted an overall response in 82.6% of patients after a median (interquartile range [IQR]) time of 10 (5-25) days. There was no difference in treatment responses between newly diagnosed and relapsed ITP patients, but newly diagnosed patients had a shorter time to response (median [IQR]: 8 [5-14] and 14 [8-27], &lt;i&gt;p&lt;/i&gt; = 0.02). Twenty-three (50%) of the patients (11/27 newly diagnosed [40.7%], 12/19 relapsed [63.2%]) required second-line ITP therapy. Thrombopoietin-receptor agonists (TPO-RAs) were the most commonly used second-line therapy with a response rate of 73.7%, and a median (IQR) time to treatment response of 15 (12-20) days. Overall response rates to TPO-RA treatment did not differ between newly diagnosed and relapsed ITP. Following the publication of novel guidelines in 2019, the median (IQR) duration of corticosteroid treatment shortened (100-52 days, &lt;i&gt;p&lt;/i&gt; = 0.01), as did the time to second-line treatment (160-47 days, &lt;i&gt;p&lt;/i&gt; = 0.01), and the median number of first-line therapies decreased from 2 (1-3) to 1 (1-2).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt; Initial treatment with corticosteroids was effective in the majority of newly diagnosed and relapsed ITP. Response rates to initial corticosteroid treatment in ITP patients are consistent with previous data, but only 50% achieve sustained remission. TPO-RAs, which are well tolerated and effective, are the most commonly used second-line therapy in our study population. International guidelines have led to faster treatment transitions and reduced splenectomy rates. Integration of real-life experience, expert consensus, and guidelines optimizes ITP patient manag","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Facial Hematoma: An Atypical Bleeding Site for Acquired Hemophilia. 面部血肿:获得性血友病的非典型出血部位。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2024-10-08 DOI: 10.1055/a-2276-4893
Neeta Kesu Belani, Winnie Z Y Teo
{"title":"Facial Hematoma: An Atypical Bleeding Site for Acquired Hemophilia.","authors":"Neeta Kesu Belani, Winnie Z Y Teo","doi":"10.1055/a-2276-4893","DOIUrl":"10.1055/a-2276-4893","url":null,"abstract":"","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baseline Platelet Count Predicts Infarct Size and Mortality after Acute Myocardial Infarction. 基线血小板计数可预测急性心肌梗死后的梗死面积和死亡率
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2024-10-04 DOI: 10.1055/a-2299-0130
Alexander Dutsch, Christian Graesser, Sophie Novacek, Johannes Krefting, Viktoria Schories, Benedikt Niedermeier, Felix Voll, Sebastian Kufner, Erion Xhepa, Michael Joner, Salvatore Cassese, Heribert Schunkert, Gjin Ndrepepa, Adnan Kastrati, Thorsten Kessler, Hendrik B Sager
{"title":"Baseline Platelet Count Predicts Infarct Size and Mortality after Acute Myocardial Infarction.","authors":"Alexander Dutsch, Christian Graesser, Sophie Novacek, Johannes Krefting, Viktoria Schories, Benedikt Niedermeier, Felix Voll, Sebastian Kufner, Erion Xhepa, Michael Joner, Salvatore Cassese, Heribert Schunkert, Gjin Ndrepepa, Adnan Kastrati, Thorsten Kessler, Hendrik B Sager","doi":"10.1055/a-2299-0130","DOIUrl":"10.1055/a-2299-0130","url":null,"abstract":"<p><strong>Introduction: </strong> Platelets greatly contribute to cardiovascular diseases. We sought to explore the association of platelet counts with infarct size and outcome in patients presenting with acute ST-segment elevation MI (STEMI) treated with primary percutaneous coronary intervention (PPCI).</p><p><strong>Methods and results: </strong> In this retrospective study, we grouped 1,198 STEMI patients into tertiles (T) based on platelet count on admission: T1 = 102-206 [10<sup>9</sup> platelets/L] (<i>n</i> = 402), T2 = 207-259 [10<sup>9</sup> platelets/L] (<i>n</i> = 396), and T3 = 260-921 [10<sup>9</sup> platelets/L] (<i>n</i> = 400). Primary endpoint was 1-year all-cause mortality. Patients with highest platelet counts on admission showed the greatest area at risk and infarct size: area at risk (median) was 22.0% (interquartile range [IQR]: 12.0-39.8%) in T1, 21.0% (IQR: 11.0-37.1%) in T2, and 26.0% (IQR: 14.9-45.0%) of the left ventricle in T3 (<i>p</i> = 0.003); final infarct sizes after 7 to 14 days were as follows: 10.0% (IQR: 2.0-21.0%) in T1, 9.0% (IQR: 2.0-20.7%) in T2, and 12.0% (IQR: 3.0-27.3%) of the left ventricle in T3 (<i>p</i> = 0.015) as serial imaging revealed. At 1 year, 16 all-cause deaths occurred in T1, 5 in T2, and 22 in T3 (log-rank test, <i>p</i> = 0.006). After adjustment, T1 and T3 were associated with all-cause 1-year mortality (T1: hazard ratio [HR] = 3.40, 95% confidence interval [CI] = 1.23-9.54, <i>p</i> = 0.02; T3: HR = 3.55, 95% CI = 1.23-9.78, <i>p</i> = 0.01) compared with T2. At 5 years, all-cause mortality remained numerically higher in the T1 and T3.</p><p><strong>Conclusions: </strong> In patients with STEMI undergoing PPCI, low and high blood platelet levels on admission were associated with increased long-term mortality (Fig. 1).</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142376342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on Tissue Factor Detection in Blood in 2024: A Narrative Review. 2024 年血液中组织因子检测的最新进展:叙述性综述。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-10-23 DOI: 10.1055/a-2381-6854
Amandine Bonifay, Sylvie Cointe, Léa Plantureux, Romaric Lacroix, Françoise Dignat-George
{"title":"Update on Tissue Factor Detection in Blood in 2024: A Narrative Review.","authors":"Amandine Bonifay, Sylvie Cointe, Léa Plantureux, Romaric Lacroix, Françoise Dignat-George","doi":"10.1055/a-2381-6854","DOIUrl":"https://doi.org/10.1055/a-2381-6854","url":null,"abstract":"<p><p>Tissue factor (TF) is a transmembrane protein essential for hemostasis. Different forms of active TF circulate in the blood, either as a component of blood cells and extracellular vesicles (EVs) or as a soluble plasma protein. Accumulating experimental and clinical evidence suggests that TF plays an important role in thrombosis. Many in-house and commercially available assays have been developed to measure TF-dependent procoagulant activity or antigen in blood and have shown promising results for the prediction of disease outcomes or the occurrence of thrombosis events in diseases such as cancer or infectious coagulopathies. This review addresses the different assays that have been published for measuring circulating TF antigen and/or activity in whole blood, cell-free plasma, and EVs and discusses the main preanalytical and analytical parameters that impact results and their interpretation, highlighting their strengths and limitations. In the recent decade, EVTF assays have been significantly developed. Among them, functional assays that use a blocking anti-TF antibody or immunocapture to measure EVTF activity have higher specificity and sensitivity than antigen assays. However, there is still a high variability between assays. Standardization and automatization are prerequisites for the measurement of EVTF in clinical laboratories.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"44 5","pages":"368-376"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms. 832例BCR-ABL阴性骨髓增生性肿瘤患者的动脉和静脉血栓栓塞并发症。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2023-10-09 DOI: 10.1055/a-2159-8767
Kai Wille, Eva Deventer, Parvis Sadjadian, Tatjana Becker, Vera Kolatzki, Karlo Hünerbein, Raphael Meixner, Marina Jiménez-Muñoz, Christiane Fuchs, Martin Griesshammer
{"title":"Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms.","authors":"Kai Wille, Eva Deventer, Parvis Sadjadian, Tatjana Becker, Vera Kolatzki, Karlo Hünerbein, Raphael Meixner, Marina Jiménez-Muñoz, Christiane Fuchs, Martin Griesshammer","doi":"10.1055/a-2159-8767","DOIUrl":"10.1055/a-2159-8767","url":null,"abstract":"<p><p>Arterial (ATE) and venous (VTE) thromboembolic complications are common causes of morbidity and mortality in <i>BCR-ABL</i>-negative myeloproliferative neoplasms (MPNs). However, there are few studies that include all MPN subtypes and focus on both MPN-associated ATE and VTE. In our single-center retrospective study of 832 MPN patients, a total of 180 first thromboembolic events occurred during a median follow-up of 6.6 years (range: 0-37.6 years), of which 105 were VTE and 75 were ATE. The probability of a vascular event at the end of the follow-up period was 36.2%, and the incidence rate for all first ATE/VTE was 2.43% patient/year. The most frequent VTE localizations were deep vein thrombosis with or without pulmonary embolism (incidence rate: 0.59% patient/year), while strokes were the most frequent ATE with an incidence rate of 0.32% patient/year. When comparing the group of patients with ATE/VTE (<i>n</i> = 180) and the group without such an event (<i>n</i> = 652) using multivariate Cox regression analyses, patients with polycythemia vera (hazard ratio [HR]: 1.660; [95% confidence interval [CI] 1.206, 2.286]) had a significantly higher risk of a thromboembolic event than the other MPN subtypes. In contrast, patients with a <i>CALR</i> mutation had a significantly lower risk of thromboembolism compared with <i>JAK2</i>-mutated MPN patients (HR: 0.346; [95% CI: 0.172, 0.699]). In summary, a high incidence of MPN-associated VTE and ATE was observed in our retrospective study. While PV patients or generally <i>JAK2</i>-mutated MPN patients had a significantly increased risk of such vascular events, this risk was reduced in <i>CALR</i>-mutated MPN patients.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"386-392"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41184199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
iTTP in der Schwangerschaft: Erfolgreiche Behandlung mit Caplacizumab. 妊娠期 iTTP:卡普珠单抗的成功治疗。
IF 2.7 4区 医学
Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2024-10-23 DOI: 10.1055/s-0044-1791987
{"title":"iTTP in der Schwangerschaft: Erfolgreiche Behandlung mit Caplacizumab.","authors":"","doi":"10.1055/s-0044-1791987","DOIUrl":"https://doi.org/10.1055/s-0044-1791987","url":null,"abstract":"","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"44 5","pages":"346"},"PeriodicalIF":2.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信